{"id":1016156,"date":"2026-11-02T12:34:58","date_gmt":"2026-11-02T17:34:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/"},"modified":"2026-11-02T12:34:58","modified_gmt":"2026-11-02T17:34:58","slug":"lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/","title":{"rendered":"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p>BEDFORD, Mass., Nov.  02, 2026  (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer\u2019s Disease (CTAD) Annual Meeting, taking place November 16 \u2013 November 19, 2026 in Boston, MA.<\/p>\n<p>Presentation details are as follows:<\/p>\n<p>\n        <strong>Date &amp; Time:\u00a0<\/strong>Monday, November 16 (2:00 p.m. ET) \u2013 Tuesday, November 17 (5:30 p.m. ET) <br \/><strong>Session Type: <\/strong>Poster<br \/><strong>Session Title:<\/strong>\u00a0MRI &amp; Imaging <\/p>\n<p>\n        <strong>Poster Number: <\/strong>P077<br \/><strong>Title:<\/strong> Detection of tau pathology in patients with early Alzheimer\u2019s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies<br \/><strong>Presenter:<\/strong>\u00a0Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular Imaging Research at Austin Health<\/p>\n<p>\n        <strong>Poster Number:<\/strong> P082<br \/><strong>Title:<\/strong> Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer\u2019s disease spectrum<br \/><strong>Presenter:<\/strong>\u00a0Gerard Nisal Bischof, PD, Director Medical Imaging at Lantheus<\/p>\n<p>\n        <strong>About\u00a0Lantheus\u00a0<\/strong><br \/>\n        <br \/>Lantheus\u202fis the\u202fleading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in\u202fMassachusetts\u202fwith offices in New Jersey,\u202fCanada,\u202fGermany,\u202fSweden,\u202fSwitzerland\u202fand the United Kingdom,\u202fLantheus\u202fhas been providing radiopharmaceutical solutions for\u202f70\u202fyears. For more information, visit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZtbbmbBF7yeiWqzoEKKKdNDgyQxkLdwK6-gjOq-Le1kddlQmzTDcm_714SxRWohl0vKX6TFsTJl-cz4NJhTuJaOY6ss2Kyaa68wXhiapxqlTb3CiimIA2zxXkXmJpPxsQ4QdyX0HCPyQPkgWvL9nZL1jVqDgJFl52lI5PeG8M_ch3PjElJVYzbGV0uIS7Cv7tqDLXIHp9QSj5hLDh9WWE94HVvvT7Si2PlP7NnbwOE9PrTnK8GjhGQ8WQXBfhqYuzNsmEbtfFGhu7wa7g1-kAAwybg_YLIR9fwBJLtIAOih6OwH4vkU5lq9DiRoKHgpcQ4jFbtG9abbYTqeDhrS-w4X7dVC3LYhIwx0V7ZLdPUNUBRhC4krp4d2wGEKjGYEFfiZUbVdGH0NaDqUHl_4ssFOycAnN3e1dbXi8TEtjqVz8l9K6sdmBeWxIlkBilyi3irNLcc_CoTtyvTIQzznR-bpIMsBVEVaUgx3kdK0o61QwFRcubQidQmwas7602_J5dkHs88l589tvwOhxZB56ScVb5bBb3FeR-z7C0g5MrN39TJoByct8mA5uPHHLXO7X_399h8XjetWhDp1Fbr_cPWJ2OCzu1OxkMphHpevVZT4j9iabSRytSRfeTiBSZlKwQFklUCq2bTn-T0YxYajTSsmx_4yirHOpgWlLMnILrz623QskhDPfmnbH00ngtqgCOFJL4lvT4YAAPvA11aJ_dw==\" rel=\"nofollow\" target=\"_blank\">www.lantheus.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Lantheus<\/strong><br \/>\n        <br \/>Mark Kinarney<br \/>Vice President, Investor Relations<br \/>978-671-8842<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zHdFFIazkInYJX5d2C4jIx24MNu3QIw-h0wznHlPH_4E2D1aIB8u_ycl1vMEr8dxJACHPLoGQyl4ukAl4A5ou6hj_-EfUdaoGOEp9vBzUVlMEfMK7RRJaymR95xG6IYcT__eK5Ct7Q_FanK-62Sjn7W6D-7W6Chw4zo9ELG4ZrL8miw9KYZyGOshGUHLG62bpn4SVT4beSqriZrp7SMDZCf9QxPJUI7Bzlft3xs7gmKIgzARQyiqepNV3SOdHGDw8seQoe3yS7xUalN97X89-Y1Ed5M4UNYJHGLg1R_6ZxvnPwHWWVj6xhJyHz-9AikF6M9UREPi5OkyOheWYyIQ9-WQusqMTSLWWgmnemn6etb3D8Oz0Rh6Bx0EL3x9BAzZCtYY2SaIV-Vu9IAm1hMQ8g9dYwtpGGSzXFVZRAwUWLFn-tocjBGoXrpJRqQsbxGS\" rel=\"nofollow\" target=\"_blank\">ir@lantheus.com<\/a><\/p>\n<p>Melissa Downs<br \/>Executive Director,\u00a0External Communications<br \/>646-975-2533<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hA2n6HGS-8QQekGJUVSDmD9-VBTwtS-SJCjqzZv7k05hy2j-dtyhf8-WJkQvWDt3r2HjIMuT1ROkP2ebeaatldsLZmzKuEoolCU-Snbac6lG691nhNAbNc62VP_geI5P333-gPSOBK2yFmJ0Upp_8FBr3KdhB2Dqy4Kt_L4EG5HI5nPOHc21_AA0eL4PopfBL_JvoT_tO41P2evcu2w7EUzvWvqqK1R6YPi3iywDx-s7O1HtMXUetPOqjcMT6SPvfeUTfMK4vaOJ0BjIPNyp8BxPQTGfuxgnhB4nQ-Q7DwhlwM_tfpMAX3W7fr1GunFvtAcbALJLJrI3-hnRHci44xNzjKRDDnnpGwud1L2f5WSsDtbKiPXbwGzO1aDLaQyAkXKLErkBDC6WAAcSOvLZasOGr1loM-fN2JmshCqviWcq76EuOX4cuts_a8uk1XqKVjTAeGgHKAnsO-b-aI0-gk7IMR2iydT8HsCS1XioJ78=\" rel=\"nofollow\" target=\"_blank\">media@lantheus.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGY1OGU0ZDMtYWYyOC00YTA5LWI2Y2UtNWMwZDhiYTE5Njk1LTEwMTkyNjMtMjAyNi0xMS0wMi1lbg==\/tiny\/Lantheus-Holdings-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer\u2019s Disease (CTAD) Annual Meeting, taking place November 16 \u2013 November 19, 2026 in Boston, MA. Presentation details are as follows: Date &amp; Time:\u00a0Monday, November 16 (2:00 p.m. ET) \u2013 Tuesday, November 17 (5:30 p.m. ET) Session Type: PosterSession Title:\u00a0MRI &amp; Imaging Poster Number: P077Title: Detection of tau pathology in patients with early Alzheimer\u2019s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studiesPresenter:\u00a0Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016156","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer\u2019s Disease (CTAD) Annual Meeting, taking place November 16 \u2013 November 19, 2026 in Boston, MA. Presentation details are as follows: Date &amp; Time:\u00a0Monday, November 16 (2:00 p.m. ET) \u2013 Tuesday, November 17 (5:30 p.m. ET) Session Type: PosterSession Title:\u00a0MRI &amp; Imaging Poster Number: P077Title: Detection of tau pathology in patients with early Alzheimer\u2019s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studiesPresenter:\u00a0Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular &hellip; Continue reading &quot;Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T17:34:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting\",\"datePublished\":\"2026-11-02T17:34:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/\"},\"wordCount\":244,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/\",\"name\":\"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=\",\"datePublished\":\"2026-11-02T17:34:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting - Market Newsdesk","og_description":"BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer\u2019s Disease (CTAD) Annual Meeting, taking place November 16 \u2013 November 19, 2026 in Boston, MA. Presentation details are as follows: Date &amp; Time:\u00a0Monday, November 16 (2:00 p.m. ET) \u2013 Tuesday, November 17 (5:30 p.m. ET) Session Type: PosterSession Title:\u00a0MRI &amp; Imaging Poster Number: P077Title: Detection of tau pathology in patients with early Alzheimer\u2019s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studiesPresenter:\u00a0Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular &hellip; Continue reading \"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-02T17:34:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting","datePublished":"2026-11-02T17:34:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/"},"wordCount":244,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/","name":"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=","datePublished":"2026-11-02T17:34:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2NzY3MCM3OTI3NDQxIzIwMDc2OTA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lantheus-announces-presentation-of-data-at-the-2026-clinical-trials-on-alzheimers-disease-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lantheus Announces Presentation of Data at the 2026 Clinical Trials on Alzheimer\u2019s Disease Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016156"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016156\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}